Clinical Trial Update: Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis [Phase 2]

View source ↗

Summary

A Phase 2 study of LY3526318 in knee osteoarthritis within the Chronic Pain Master Protocol has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis
• Osteoarthritis of the Knee

Drugs mentioned

• LY3526318 (LY3526318)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Osteoarthritis, Osteo Arthritis Knee | Phase 2 | Status: COMPLETED | Results posted: 2023-09-06